

Rahvusvahelised

(eesti autorid või rahvusvahelised töörühmad paksus kirjas)

- 2017**
1. **Aareleid T, Zimmermann M-L, Baburin A, Innos K.** Divergent trends in lung cancer incidence by gender, age and histological type in Estonia: a nationwide population-based study. *BMC Cancer* 2017;17:596.
<https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3605-x>
 2. Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, Carreira H, Spika D, Marcos-Gragera R, Peris-Bonet R, Piñeros M, Sant M, Kuehni CE, Murphy MFG, Coleman MP, Allemani C; **CONCORD Working Group.** Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. *Lancet Haematol* 2017;4:e202–17.
[http://www.thelancet.com/journals/lanhae/article/PIIS2352-3026\(17\)30052-2/fulltext](http://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30052-2/fulltext)
 3. Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, Comber H, Dimitrova N, Leinonen MK, Siesling S, van der Zwan JM, Van Eycken L, Visser O, Žakelj MP, Anderson LA, Bella F, **Innos K**, Otter R, Stiller CA, Trama A; **RARECAREnet** working group. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. *Lancet Oncol* 2017;18:1022–39.
[http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(17\)30445-X/fulltext](http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30445-X/fulltext)
 4. Gatta G, Peris-Bonet R, Visser O, Stiller C, Marcos-Gragera R, Sánchez MJ, Lacour B, Kaatsch P, Berrino F, Rutkowski S, Botta L; **EUROCARE-5 Working Group.** Geographical variability in survival of European children with central nervous system tumours. *Eur J Cancer* 2017;82:137–148.
[http://www.ejancer.com/article/S0959-8049\(17\)30983-8/fulltext](http://www.ejancer.com/article/S0959-8049(17)30983-8/fulltext)
 5. Gatta G, Trama A, Capocaccia R; **RARECAREnet Working Group.** Epidemiology of rare cancers and inequalities in oncologic outcomes. *Eur J Surg Oncol* 2017 [Epub ahead of print]
[http://www.ejso.com/article/S0748-7983\(17\)30685-6/fulltext](http://www.ejso.com/article/S0748-7983(17)30685-6/fulltext)
 6. Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, Frstrup CW, Mortensen MB, Primić-Žakelj M, Zadnik V, Becker N, Hackert T, **Mägi M**, Cassetti T, Sassatelli R, Grützmann R, Merkel S, Gonçalves AF, Bento MJ, Hegyi P, Lakatos G, Szentesi A, Moreau M, van de Velde T, Broeks A, Sant M, Minicozzi P, Mazzaferro V, Real FX, Carrato A, Molero X, Besselink MG, Malats N, Büchler MW, Schrotz-King P, Brenner H. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. *Gut* 2017 [Epub ahead of print]
<http://gut.bmj.com/content/early/2017/11/20/gut.jnl-2017-314828.long>
 7. **Innos K, Baburin A**, Kotsar A, Eiche I-E, **Lang K.** Prostate cancer incidence, mortality and survival trends in Estonia 1995–2014. *Scand J Urol* 2017;51:442–449.
<http://www.tandfonline.com/eprint/NDqJhd9MKjzc9WcStPE/full>
 8. Islami F, Ferlay J, Lortet-Tieulent J, Bray F, Jemal A. International trends in anal cancer incidence rates. *Int J Epidemiol* 2017;46:924–938.
<https://academic.oup.com/ije/article-abstract/doi/10.1093/ije/dyw276/2447873/International-trends-in-anal-cancer-incidence?redirectedFrom=fulltext>
 9. Lykoudis PM, Partelli S, Muffatti F, Caplin M, Falconi M, Fusai GK; **RARECAREnet**

- Working Group.** Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours. *Eur J Surg Oncol* 2017 [Epub ahead of print]
[http://www.ejso.com/article/S0748-7983\(17\)30941-1/fulltext](http://www.ejso.com/article/S0748-7983(17)30941-1/fulltext)
10. Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C; **CONCORD Working Group.** Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). *Gynecol Oncol* 2017;144:396–404.
[http://www.gynecologiconcology-online.net/article/S0090-8258\(16\)31575-X/fulltext](http://www.gynecologiconcology-online.net/article/S0090-8258(16)31575-X/fulltext)
 11. Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, Allemani C; & the **CONCORD Working Group.** The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (**CONCORD-2**). *Gynecol Oncol* 2017;144:405–413.
[http://www.gynecologiconcology-online.net/article/S0090-8258\(16\)31497-4/fulltext](http://www.gynecologiconcology-online.net/article/S0090-8258(16)31497-4/fulltext)
 12. Minicozzi P, **Innos K**, Sánchez MJ, Trama A, Walsh P, Marcos-Gragera R, Dimitrova N, Botta L, Visser O, Rossi S, Tavilla A, Sant M, the EURO CARE-5 Working Group. Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EURO CARE-5 study. *Eur J Cancer* 2017;84:335–53.
[http://www.ejancer.com/article/S0959-8049\(17\)31125-5/fulltext](http://www.ejancer.com/article/S0959-8049(17)31125-5/fulltext)
 13. **Ojamaa K, Veerus P, Baburin A, Everaus H, Innos K.** Trends in ovarian cancer survival in Estonia by age and stage. *Int J Gynecol Cancer* 2017;27:44–9.
http://journals.lww.com/ijgc/Abstract/2017/01000/Time_Trends_in_Ovarian_Cancer_Survival_in_Estonia.9.aspx
 14. **Paapsi K, Mägi M, Mikkel S, Saks K, Aareleid T, Innos K.** Impact of under-reporting of cases on the estimates of childhood cancer incidence and survival in Estonia. *Eur J Cancer Prev* 2017;26:S147–52.
http://journals.lww.com/eurjancerprev/Abstract/2017/09001/The_impact_of_under_reporting_of_cases_on_the.4.aspx
 15. **Padrik P, Valter A, Valter E, Baburin A, Innos K.** Trends in incidence and survival of cutaneous malignant melanoma in Estonia: a population-based study. *Acta Oncol* 2017;56:52–8.
<http://www.tandfonline.com/doi/abs/10.1080/0284186X.2016.1243804?journalCode=ionc20>
 16. Pasquali S, Bonvalot S, Tzanis D, Casali PG, Trama A, Gronchi A; **RARECARENet Working Group.** Treatment challenges in and outside a network setting: Soft tissue sarcomas. *Eur J Surg Oncol* 2017 [Epub ahead of print]
[http://www.ejso.com/article/S0748-7983\(17\)30705-9/fulltext](http://www.ejso.com/article/S0748-7983(17)30705-9/fulltext)
 17. Ray-Coquard I, Trama A, Seckl MJ, Fotopoulou C, Pautier P, Pignata S, Kristensen G, Mangili G, Falconer H, Massuger L, Sehouli J, Pujade-Lauraine E, Lorusso D, Amant F, Rokkones E, Vergote I, Ledermann JA; **RARECARENet Working Group.** Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. *Eur J Surg Oncol* 2017 Nov 3 [Epub ahead of print]
[http://www.ejso.com/article/S0748-7983\(17\)30947-2/fulltext](http://www.ejso.com/article/S0748-7983(17)30947-2/fulltext)
 18. Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, Hesselting P, Shin HY, Stiller CA; **IICC-3 contributors.** International incidence of childhood cancer, 2001-10: a population-based registry study. *Lancet Oncol* 2017;18:719–731.
[http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(17\)30186-9/fulltext](http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30186-9/fulltext)
 - 2016 19. **Baburin A, Aareleid T, Rahu M, Reedik L, Innos K.** Recent changes in breast cancer

- incidence and mortality in Estonia: transition to the West. *Acta Oncol* 2016;55:728–33.
<http://www.tandfonline.com/doi/full/10.3109/0284186X.2015.1125014>
20. Vaccarella S, Franceschi S, Zaridze D, Poljak M, **Veerus P**, Plummer M, Bray F. Preventable fractions of cervical cancer via effective screening in six Baltic, central, and eastern European countries 2017-40: a population-based study. *Lancet Oncol* 2016 Oct;17(10):1445-1452.
[http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(16\)30275-3/fulltext](http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30275-3/fulltext)
- 2015** 21. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP; **CONCORD Working Group**. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet* 2015;385:977–1010.
[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(14\)62038-9/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62038-9/abstract)
22. Anderson LA, Tavilla A, Brenner H, Luttmann S, Navarro C, Gavin AT, Holleczeck B, Johnston BT, Cook MB, Bannon F, Sant M; **EUROCARE-5 Working Group**. Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: results from EUROCARE-5. *Eur J Cancer* 2015;51:2144–57.
[http://www.ejancer.com/issue/S0959-8049\(15\)X0017-7](http://www.ejancer.com/issue/S0959-8049(15)X0017-7)
23. Baili P, Di Salvo F, Marcos-Gragera R, Siesling S, Mallone S, Santaquilani M, Micheli A, Lillini R, Francisci S; **EUROCARE-5 Working Group**. Age and case mix-standardised survival for all cancer patients in Europe 1999-2007: Results of EUROCARE-5, a population-based study. *Eur J Cancer* 2015;51:2120–29.
[http://www.ejancer.com/issue/S0959-8049\(15\)X0017-7](http://www.ejancer.com/issue/S0959-8049(15)X0017-7)
24. Crocetti E, Mallone S, Robsahm TE, Gavin A, Domenic A, Ardanaz E, Lopez MC, **Innos K**, Minicozzi P, Borgognoni L, Pierannunzio D, Eisemann N; **EUROCARE-5 Working Group**. Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study. *Eur J Cancer* 2015;51:2179–90.
[http://www.ejancer.com/issue/S0959-8049\(15\)X0017-7](http://www.ejancer.com/issue/S0959-8049(15)X0017-7)
25. De Angelis R, Minicozzi P, Sant M, Dal Maso L, Brewster DH, Osca-Gelis G, Visser O, Maynadić M, Marcos-Gragera R, Troussard X, Agius D, Roazzi P, Meneghini E, Monnereau A; **EUROCARE-5 Working Group**. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000-2007: Results of EUROCARE-5 population-based study. *Eur J Cancer* 2015;51:2154–68.
[http://www.ejancer.com/issue/S0959-8049\(15\)X0017-7](http://www.ejancer.com/issue/S0959-8049(15)X0017-7)
26. Francisci S, Minicozzi P, Pierannunzio D, Ardanaz E, Eberle A, Grimsrud TK, Knijn A, Pastorino U, Salmerón D, Trama A, Sant M; **EUROCARE-5 Working Group**. Survival patterns in lung and pleural cancer in Europe 1999-2007: Results from the EUROCARE-5 study. *Eur J Cancer* 2015;51:2142–53.
[http://www.ejancer.com/issue/S0959-8049\(15\)X0017-7](http://www.ejancer.com/issue/S0959-8049(15)X0017-7)
27. Gatta G, Botta L, Sánchez MJ, Anderson LA, Pierannunzio D, Licitra L; **EUROCARE-5 Working Group**. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. *Eur J Cancer* 2015;51:2130–43.
[http://www.ejancer.com/issue/S0959-8049\(15\)X0017-7](http://www.ejancer.com/issue/S0959-8049(15)X0017-7)
28. Holleczeck B, Rossi S, Domenic A, **Innos K**, Minicozzi P, Francisci S, Hackl M, Eisemann N, Brenner H; **EUROCARE-5 Working Group**. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – Results from the EUROCARE-5 study. *Eur J Cancer* 2015;51:2158–68.
[http://www.ejancer.com/issue/S0959-8049\(15\)X0017-7](http://www.ejancer.com/issue/S0959-8049(15)X0017-7)
29. **Innos K, Lang K, Pärna K, Aareleid T**. Age-specific cancer survival in Estonia: recent

trends and data quality. *Clin Epidemiol* 2015;7:355–62.

<https://www.dovepress.com/age-specific-cancer-survival-in-estonia-recent-trends-and-data-quality-peer-reviewed-article-CLEP>

30. **Innos K, Padrik P, Valvere V, Aareleid T.** Sex differences in cancer survival in Estonia: a population-based study. *BMC Cancer* 2015;15:72.
<http://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1080-9>
31. Lepage C, Capocaccia R, Hackl M, Lemmens V, Molina E, Pierannunzio D, Sant M, Trama A, Faivre J; **EUROCARE-5 Working Group.** Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: Results of EUROCARE-5. *Eur J Cancer* 2015;51:2169–78.
[http://www.ejancer.com/issue/S0959-8049\(15\)X0017-7](http://www.ejancer.com/issue/S0959-8049(15)X0017-7)
32. Li P, Znaor A, Holcatova I, Fabianova E, Mates D, Wozniak MB, Ferlay J, Scelo G. Regional geographic variations in kidney cancer incidence rates in European countries. *Eur Urol* 2015;67:1134–41.
<http://www.sciencedirect.com/science/article/pii/S0302283814011750>
33. Marcos-Gragera R, Mallone S, Kiemeny LA, Vilardell L, Malats N, Allory Y, Sant M; **EUROCARE-5 Working Group.** Urinary tract cancer survival in Europe 1999-2007: Results of the population-based study EUROCARE-5. *Eur J Cancer* 2015;51:2117–30.
[http://www.ejancer.com/issue/S0959-8049\(15\)X0017-7](http://www.ejancer.com/issue/S0959-8049(15)X0017-7)
34. Mounier M, Bossard N, Remontet L, Belot A, Minicozzi P, De Angelis R, Capocaccia R, Iwaz J, Monnereau A, Troussard X, Sant M, Maynadié M, Giorgi R; **EUROCARE-5 Working Group; CENSUR Working Survival Group.** Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5). *Lancet Haematol* 2015;2:e481–491.
[http://www.thelancet.com/journals/lanhae/article/PIIS2352-3026\(15\)00155-6/fulltext](http://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(15)00155-6/fulltext)
35. Rossi S, Baili P, Capocaccia R, Caldora M, Carrani E, Minicozzi P, Pierannunzio D, Santaquilani M, Trama A, Allemani C, Belot A, Buzzoni C, Lorez M, De Angelis R; **EUROCARE-5 Working Group.** The EUROCARE-5 study on cancer survival in Europe 1999-2007: database, quality checks and statistical analysis methods. *Eur J Cancer* 2015;51:2104–19.
[http://www.ejancer.com/issue/S0959-8049\(15\)X0017-7](http://www.ejancer.com/issue/S0959-8049(15)X0017-7)
36. Sant M, Chirlaque Lopez MD, Agresti R, Sánchez Pérez MJ, Holleczeck B, Bielska-Lasota M, Dimitrova N, **Innos K**, Katalinic A, Langseth H, Larrañaga N, Rossi S, Siesling S, Minicozzi P; **EUROCARE-5 Working Group.** Survival of women with cancers of breast and genital organs in Europe 1999–2007: Results of the EUROCARE-5 study. *Eur J Cancer* 2015;51:2191–205.
[http://www.ejancer.com/issue/S0959-8049\(15\)X0017-7](http://www.ejancer.com/issue/S0959-8049(15)X0017-7)
37. Steliarova-Foucher E, Stiller C, Colombet M, Kaatsch P, Zanetti R, Peris-Bonet R. Registration of childhood cancer: Moving towards pan-European coverage? *Eur J Cancer* 2015;51:1064–79.
[http://www.ejancer.com/article/S0959-8049\(15\)00225-7/abstract](http://www.ejancer.com/article/S0959-8049(15)00225-7/abstract)
38. Trama A, Foschi R, Larrañaga N, Sant M, Fuentes-Raspall R, Serraino D, Tavilla A, Van Eycken L, Nicolai N; **EUROCARE-5 Working Group.** Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: Results from the EUROCARE-5 study. *Eur J Cancer* 2015;51:2106–16.
[http://www.ejancer.com/issue/S0959-8049\(15\)X0017-7](http://www.ejancer.com/issue/S0959-8049(15)X0017-7)
39. Visser O, Ardanaz E, Botta L, Sant M, Tavilla A, Minicozzi P; **EUROCARE-5 Working Group.** Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCARE-5 study. *Eur J Cancer* 2015;51:2131–41.

- [http://www.ejcancer.com/issue/S0959-8049\(15\)X0017-7](http://www.ejcancer.com/issue/S0959-8049(15)X0017-7)
- 2014** 40. **Baburin A, Aareleid T, Padrik P, Valvere V, Innos K.** Time trends in population-based breast cancer survival in Estonia: analysis by age and stage. *Acta Oncol* 2014;53:226–34.
<http://www.tandfonline.com/doi/full/10.3109/0284186X.2013.806992#.Vp0kXip974Y>
41. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R; **EUROCARE-5 Working Group.** Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. *Lancet Oncol* 2014;15:23–34.
[http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(13\)70546-1/abstract](http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70546-1/abstract)
42. Gatta G, Botta L, Rossi S, **Aareleid T**, Bielska-Lasota M, Clavel J, Dimitrova N, Jakab Z, Kaatsch P, Lacour B, Mallone S, Marcos-Gragera R, Minicozzi P, Sánchez-Pérez MJ, Sant M, Santaquilani M, Stiller C, Tavilla A, Trama A, Visser O, Peris-Bonet R, **the EUROCARE Working Group.** Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study. *Lancet Oncol* 2014;15:35–47.
[http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(13\)70548-5/abstract](http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70548-5/abstract)
43. **Innos K, Baburin A, Aareleid T.** Cancer patient survival in Estonia 1995–2009: time trends and data quality. *Cancer Epidemiol* 2014;38:253–8.
[http://www.cancerepidemiology.net/article/S1877-7821\(14\)00059-9/abstract](http://www.cancerepidemiology.net/article/S1877-7821(14)00059-9/abstract)
44. Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczeck B, Marcos-Gragera R, Maynadić M, Monnereau A, Osca-Gelis G, Visser O, De Angelis R; **EUROCARE-5 Working Group.** Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. *Lancet Oncol* 2014;15:931–42.
[http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(14\)70282-7/abstract](http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70282-7/abstract)
45. Simard EP, Torre LA, Jemal A. International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site. *Oral Oncol* 2014;50:387–403.
[http://www.oraloncology.com/article/S1368-8375\(14\)00032-3/abstract](http://www.oraloncology.com/article/S1368-8375(14)00032-3/abstract)
- 2013** 46. Allemani C, Rachet B, Weir HK, Richardson LC, Lepage C, Faivre J, Gatta G, Capocaccia R, Sant M, Baili P, Lombardo C, **Aareleid T**, Ardanaz E, Bielska-Lasota M, Bolick S, Cress R, Elferink M, Fulton JP, Galceran J, Gózd S, Hakulinen T, Primic-Zakelj M, Rachtan J, Diba CS, Sánchez MJ, Schymura MJ, Shen T, Tagliabue G, Tumino R, Vercelli M, Wolf HJ, Wu XC, Coleman MP. Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. *BMJ Open* 2013;3(9):e003055.
47. Allemani C, Sant M, Weir HK, Richardson LC, Baili P, Storm H, Siesling S, Torrella-Ramos A, Voogd AC, **Aareleid T**, Ardanaz E, Berrino F, Bielska-Lasota M, Bolick S, Cirilli C, Colonna M, Contiero P, Cress R, Crocetti E, Fulton JP, Grosclaude P, Hakulinen T, Izarzugaza MI, Malmström P, Peignaux K, Primic-Žakelj M, Rachtan J, Safaei Diba C, Sánchez MJ, Schymura MJ, Shen T, Traina A, Tryggvadottir L, Tumino R, Velten M, Vercelli M, Wolf HJ, Woronoff AS, Wu X, Coleman MP. Breast cancer survival in the US and Europe: a CONCORD high-resolution study. *Int J Cancer* 2013;132:1170–81.
48. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, Rosenberg PS, Bray F, Gillison ML. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. *J Clin Oncol* 2013;31:4550–9.
49. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur J Cancer* 2013;49:1374–403.
50. Mallone S, De Angelis R, van der Zwan JM, Trama A, Siesling S, Gatta G, Capocaccia R; **RARECARE WG.** Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project. *Cancer Epidemiol* 2013;37:850–6.

51. **Rahu K**, Auvinen A, Hakulinen T, **Tekkel M**, Inskip PD, Bromet EJ, Boice JD Jr, **Rahu M**. Chernobyl cleanup workers from Estonia: follow-up for cancer incidence and mortality. *J Radiol Prot* 2013;33:395–411.
52. **Rahu K**, Hakulinen T, Smailyte G, Stengrevics A, Auvinen A, Inskip PD, Boice JD Jr, **Rahu M**. Site-specific cancer risk in the Baltic cohort of Chernobyl cleanup workers 1986–2007. *Eur J Cancer* 2013;49:2926–33.
53. Verhoeven RH, Janssen-Heijnen ML, Saum KU, Zanetti R, Caldarella A, Holleczeck B, Brewster DH, Hakulinen T, Horenblas S, Brenner H, Gondos A; **EUNICE Survival Working Group**. Population-based survival of penile cancer patients in Europe and the United States of America: no improvement since 1990. *Eur J Cancer* 2013;49:1414–21.
54. Verhoeven RHA, Gondos A, Janssen-Heijnen MLG, Saum KU, Brewster DH, Holleczeck B, Crocetti E, Rosso S, Hakulinen T, **Aareleid T**, Brenner H. Testicular cancer in Europe and the USA: survival still rising among older patients. *Ann Oncol* 2013;24:508–13.
- 2012 55. **Innos K**, **Soplepmann J**, **Suuroja T**, **Melnik P**, **Aareleid T**. Survival for colon and rectal cancer in Estonia: Role of staging and treatment. *Acta Oncol* 2012;51:521–7.
56. Neppl-Huber C, Zappa M, Coebergh JW, Rapiti E, Rachtan J, Holleczeck B, Rosso S, **Aareleid T**, Brenner H, Gondos A; **EUNICE Survival Working Group**. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. *Ann Oncol* 2012;23:1325–34.
- 2011 57. **Aareleid T**, Gondos A, Brenner H, **Pokker H**, **Leppik K**, **Mägi M**. Testicular cancer survival in Estonia: improving but still relatively low. *Acta Oncol* 2011;50:99–105.
58. Arbyn M, Antoine J, **Mägi M**, Smailyte G, Stengrevics A, Suteu O, Valerianova Z, Bray F, Weiderpass E. Trends in cervical cancer incidence and mortality in the Baltic countries, Bulgaria and Romania. *Int J Cancer* 2011;128:1899–907.
59. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, Trama A, Capocaccia R; **RARECARE working group**. Rare cancers are not so rare: the rare cancer burden in Europe. *Eur J Cancer* 2011;47:2493–511.
60. **Innos K**, **Mägi M**, **Tekkel M**, **Aareleid T**. Place of residence predicts breast cancer stage at diagnosis in Estonia. *Eur J Pub Health* 2011;21:376–80.
- 2010 61. Allemani C, Storm H, Voogd AC, Holli K, Izarzugaza I, Torrella-Ramos A, Bielska-Lasota M, **Aareleid T**, Ardanaz E, Colonna M, Crocetti E, Danzon A, Federico M, Garau I, Grosclaude P, Hédelin G, Martínez-García C, Peignaux K, Plesko I, Primic-Zakelj M, Rachtan J, Tagliabue G, Tumino R, Traina A, Tryggvadóttir L, Vercelli M, Sant M. Variation in 'standard care' for breast cancer across Europe: a EUROCORE-3 high resolution study. *Eur J Cancer* 2010;46:1528–36.
62. Arbyn M, Antoine J, Valerianova Z, **Mägi M**, Stengrevics A, Smailyte G, Suteu O, Micheli A. Trends in cervical cancer incidence and mortality in Bulgaria, Estonia, Latvia, Lithuania and Romania. *Tumori* 2010;96:517–23.
63. Gatta G, Capocaccia R, Trama A, Martínez-García C; **RARECARE Working Group**. The burden of rare cancers in Europe. *Adv Exp Med Biol* 2010;686:285–303.
64. Gatta G, Zigon G, **Aareleid T**, Ardanaz E, Bielska-Lasota M, Galceran J, Gózdź S, Hakulinen T, Martínez-García C, Plesko I, Zakelj MP, Rachtan J, Tagliabue G, Vercelli M, Faivre J. Patterns of care for European colorectal cancer patients diagnosed 1996–1998: a EUROCORE high resolution study. *Acta Oncol* 2010;49:776–83.
65. Lepage C, Ciccolallo L, De Angelis R, Bouvier AM, Faivre J, Gatta G; **EUROCORE working group**. European disparities in malignant digestive endocrine tumours survival. *Int J Cancer* 2010;126:2928–34.
66. Rosso S, Gondos A, Zanetti R, Bray F, Zakelj M, Zagar T, Smailyte G, Ponti A, Brewster DH, Voogd AC, Crocetti E, Brenner H; **EUNICE Survival Working Group**. Up-to-date estimates of breast cancer survival for the years 2000–2004 in 11 European countries: the role of screening and a comparison with data from the United States. *Eur J Cancer* 2010;46:3351–

02.01.2018

- 7.
- 2009** 67. Gondos A, Bray F, Hakulinen T, Brenner H; **EUNICE Survival Working Group**. Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. *Ann Oncol* 2009;20:564–73.
68. Gondos A, Holleccek B, Janssen-Heijnen M, Brewster DH, Bray F, Rosso S, Hakulinen T, Brenner H; **EUNICE Survival Working Group**. Model-based projections for deriving up-to-date cancer survival estimates: an international evaluation. *Int J Cancer* 2009;125:2666–72.
69. **Lang K**. Ethnic differences in cancer incidence in Estonia: two cross-sectional unlinked census-based cancer incidence analyses. *Popul Health Metr* 2009;7:10.

Eestikeelsed

- 2017** 1. Zimmermann M-L, Innos K, Härmaorg P, Mägi M, Baburin A, Aareleid T. Vähihaigestumus 2009–2013 ja 20 aasta trendid Eestis. Eesti Arst 2017;96:11–20.
- 2016** 2. Rahu K, Rahu M. Tšernobõli veteranide Eesti kohortuuring: vähihaigestumus 1986–2012 ja suremus 1986–2014. Eesti Arst 2016;95:575–80.
3. Innos K, Aareleid T. Vähielulemuse suurenemine Eestis aastatel 2010–2014 jätkus. Eesti Arst 2016;95:366–72.
- 2015** 4. Innos K, Aareleid T. Eakate vähielulemus Eestis 2005–2009. Eesti Arst 2015;94:589–94.
5. Jaal J, Kase M, Jõgi T, Tammaru M, Ojamaa K, Mägi M. Vähihaigestumus Eesti eakate hulgas ajavahemikul 1980–2012. Eesti Arst 2015;94:583–7.
6. Orumaa M, Lang K, Mägi M, Pärna K, Aareleid T, Innos K. Eesti Vähiregistri andmete valiidus aastatel 1995–2008. Eesti Arst 2015;94:339–46.
- 2014** 7. Jaal J, Kase M, Jõgi T, Tammaru M, Ojamaa K, Mägi M. Kilpnäärmevähi haigestumus 15–44aastaste Eesti noorte hulgas ajavahemikul 1980–2009. Eesti Arst 2014;93:414–7.
8. Jaal J, Kase M, Jõgi T, Tammaru M, Ojamaa K, Mägi M. Vähihaigestumus 15–44aastaste Eesti noorte hulgas ajavahemikul 1980–2009. Eesti Arst 2014;93:369–73.
9. Joonalu M, Mägi M, Kase M, Jõgi T, Tammaru M, Ojamaa K, Asser T, Jaal J. Peaaju primaarsetesse pahaloomulistes kasvajatesse haigestumus 15–44aastaste Eesti noorte hulgas ajavahemikul 1980–2009. Eesti Arst 2014;93:410–3.
10. Jõgi T, Mägi M, Kase M, Tammaru M, Ojamaa K, Jaal J. Kopsuvähi haigestumus 15–44aastaste Eesti noorte hulgas ajavahemikul 1980–2009. Eesti Arst 2014;93:381–4.
11. Kuusk G, Mägi M, Kase M, Jõgi T, Tammaru M, Ojamaa K, Jaal J. Naha pahaloomulistes kasvajatesse haigestumus 15–44aastaste Eesti noorte hulgas ajavahemikul 1980–2009. Eesti Arst 2014;93:386–90.
12. Niinepuu K, Mägi M, Kase M, Jõgi T, Tammaru M, Ojamaa K, Jaal J. Eesnäärmevähi ja munandivähi haigestumus 15–44aastaste Eesti meeste hulgas ajavahemikul 1980–2009. Eesti Arst 2014;93:399–402.
13. Ojamaa K, Tammaru M, Kase M, Mägi M, Jõgi T, Jaal J. Günekoloogilistes pahaloomulistes kasvajatesse haigestumus 15–44aastaste Eesti noorte naiste hulgas ajavahemikul 1980–2009. Eesti Arst 2014;93:395–8.
14. Ojamaa K, Tammaru M, Kase M, Mägi M, Jõgi T, Jaal J. Rinnavähi haigestumus 15–44aastaste Eesti noorte naiste hulgas ajavahemikul 1980–2009. Eesti Arst 2014;93:391–3.
15. Pihlak P, Mägi M, Kase M, Jõgi T, Tammaru M, Ojamaa K, Jaal J. Neeruvähi ja kusepõievähi haigestumus 15–44aastaste Eesti inimeste hulgas ajavahemikul 1980–2009. Eesti Arst 2014;93:405–8.
16. Saretok M, Mägi M, Kase M, Jõgi T, Tammaru M, Ojamaa K, Jaal J. Maovähi ja kolorektaalvähi haigestumus 15–44aastaste Eesti noorte hulgas ajavahemikul 1980–2009. Eesti Arst 2014;93:375–9.
- 2013** 17. Innos K, Aareleid T. Vähielulemus Eestis 2005–2009. Eesti Arst 2013;92:437–42.
- 2012** 18. Aareleid T, Mägi M. Vähielulemus Eestis võrdluses teiste Euroopa riikidega aastatel 1990–2009 EUNICE elulemusuuringu alusel. Eesti Arst 2012;91:587–93.
- 2010** 19. Jaal J, Mägi M. Viimaste aastakümnete suundumused kopsuvähi epidemioloogias. Eesti Arst 2010;2009(Lisa 2):5–11.
- 2009** 20. Mägi M, Aareleid T. Vähihaigestumus ja selle muutused Eestis. Eesti Arst 2009;88:635–40.